Houston — home to the Texas Medical Center — has made the cut for top life science metros. Photo via Getty Images

Of the top 25 United States metros ranked as the best for life science, Houston came in at lucky No. 13.

CommercialCafe issued a report this month ranking the top 25 U.S. cities for life science, factoring in volume of life science patents, number of life science establishments, size of workforce, educational institutions, office market, and more.

Houston stood out on the report for a few metrics. It might not be surprising, as Houston is home to the world's largest medical center, but the city boasts the 10th largest workforce with 5,100 workers employed in industry related occupations, the report found. Additionally, the city ranked:

  • No. 8 for life science education — more than 860,000 area residents aged 25 years or older hold a bachelor’s degree in an industry related field.
  • No. 9 for life science establishments — which has increased 23 percent since 2018 to a total of nearly 3,300.
  • No. 9 for life science square footage added — with roughly 840,000 square feet of new life sciences projects currently in development

As positive as the report finds Houston's life science market, the ranking represents a decrease in ranking compared to 2022 where Houston scored a spot in the top 10. In fact, Houston can't even claim the top spot in the Lone Star State. No Texas cities made the top 10, but the Dallas area secured the No. 11 ranking. Dallas was also ranked highly for its talent pool.

Meanwhile in central Texas, Austin claimed the No. 22 spot. The full ranking is below.

www.commercialcafe.com

Conveniently, CBRE, which also ranks the top life science markets every year, agrees with CommercialCafe's ranking of Houston. The 2023 report placed Houston at No. 13, which is exactly where the Bayou City ranked in 2022. However, according to CBRE, Houston ranks ahead of Dallas and Austin, which both still claimed rankings in the top 25.

The Bayou City also ranks as the No. 1 life science market in the state. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Report: Houston ranks in the top 10 life sciences markets in the U.S.

rising star

Houston has received a big thumbs-up in a new study ranking the country’s top metro areas for life sciences companies to launch or grow.

The study, published by commercial real estate platform CommercialCafe, puts Houston at No. 10 among the top U.S. metros in the life sciences sector and No. 1 in Texas. Boston topped CommercialCafe’s ranking, with Dallas-Fort Worth at No. 16, San Antonio at No. 29, and Austin at No. 37.

For the study, CommercialCafe examined various factors that support the success of a life sciences ecosystem. The study encompassed 45 major metros in the U.S. Among the highlights for Houston:

  • No. 9 ranking for educational attainment, with 733,577 of residents ages 25 year and older holding at least a bachelor’s degree in science, engineering, or an engineering-related field.
  • No. 12 ranking for life sciences projects under development (a little over 817,000 square feet). Overall, the life sciences sector occupies roughly 2.3 million square feet in the Houston area.

Last month, commercial real estate services company CBRE put Houston at No. 13 among the country’s top 25 clusters for life sciences research talent. DFW appeared at No. 16 and Austin at No. 18.

In assessing Houston’s strength in life sciences, CommercialCafe says that “the resilient Texas powerhouse was lifted by the wave of emerging life sciences clusters across the U.S.”

Two major projects are helping Houston maintain that powerhouse status. The Texas Medical Center (TMC) last year unveiled TMC3, a 37-acre, roughly 6 million-square-foot life sciences campus, and Houston-based Hines recently topped out the 270,000-square-foot first phase of the 53-acre Levit Green life sciences district next to TMC.

“Houston is already fortunate to have such a strong healthcare and higher education ecosystem. The TMC3 project stands to be the cornerstone of our regional life sciences strategy. It will create new jobs, [and] advance innovative medical technologies and healthcare solutions,” Houston Mayor Sylvester Turner said in 2021.

According to Greater Houston Partnership data, the Houston area is home to Houston has more than 1,760 life sciences companies, hospitals, health care facilities, and research institutions. Collectively, the life sciences and healthcare sectors employ 320,500 people in the region.

Women in science, technology, engineering, and mathematics are well represented in Houston, according to a recent report. Photo via Christina Morillo/Pexels

Houston named a top city for women in STEM fields

who runs the world?

If you're a woman in science, technology, engineering, or mathematics and you call Houston home, according to a new report, you're doing it right.

In honor of Women's History Month, CommercialCafe updated its 2020 ranking of the top U.S. cities for women working in STEM. According to the report, Houston ranks at No. 5 on the list of the best southern cities in the United States for women in STEM. The Bayou City also claims the No. 19 spot nationally.

Here are some other key findings about Houston on the report:

  • STEM jobs in Houston account for 7 percent of all jobs, and a little less than a third of these positions are held by women.
  • About 23,964 women work in STEM in Houston — which is the most out of any other city in the South.
  • Houston gained 4,318 new women STEM employees since 2015, the third-highest number in this regional ranking.
  • The median annual income for women in STEM here is $68,172.
Texas makes up about half of the top 10 Southern states — Austin places in second, while Frisco (No. 7), Dallas (No. 8) and Plano (No. 10) fall behind Houston. Nationally, New York City, San Francisco, and Seattle take the top three spots, respectively.

Women working in STEM - South 2021 - Infograminfogram.com

Houston has been recognized for its STEM fields before, and last fall, SmartAsset ranked Houston as No. 7 in STEM nationally based on workforce size. And, in 2019, Houston placed sixth for STEM workforce diversity. Last year Houston also ranked No. 6 for women in tech, also according to SmartAsset.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.